March 6, 2019
Bayer said on March 5 that it has filed a new drug application in Japan for darolutamide, a non-steroidal androgen receptor antagonist, for the treatment of castration-resistant prostate cancer (CRPC). The filing is based on data from the PIII ARAMIS...read more